Recap: Biomarin Pharmaceutical Q3 Earnings


Biomarin Pharmaceutical BMRN reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.


Biomarin Pharmaceutical missed estimated earnings by 300.0%, reporting an EPS of $-0.04 versus an estimate of $-0.01.

Revenue was up $96.60 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.48 which was followed by a 5.18% increase in the share price the next day.

Here's a look at Biomarin Pharmaceutical's past performance:

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.11 -0.32 -0.25
EPS Actual 0.59 0.17 -0.32 -0.20
Revenue Estimate 521.47M 507.52M 442.39M 435.32M
Revenue Actual 533.80M 519.36M 449.81M 408.74M

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!